Phase II Trial of Dual LAG-3–PD-1 Inhibition With Neoadjuvant Relatlimab + Nivolumab in Resectable Stage III Melanoma

Short slideset on second-generation TRK inhibitors selitrectinib and repotrectinib in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: November 9, 2021

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Short expert slideset on when and how to test for NTRK fusions in various solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 8, 2021

On-demand webcast describing how to incorporate new data into current treatment algorithms in melanoma presented by Clinical Care Options (CCO)

Jeffrey S. Weber, MD, PhD
Program Director Allison Betof Warner, MD, PhD Hussein Tawbi, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: September 29, 2021 Expired: September 28, 2022